Current approach to the options of primary and secondary prevention of ischemic cerebrovascular accident
Authors:
MUDr. Vladimír Rohan; Ph.D. MUDr. Jiří Polívka 1; CSc. MUDr. Petr Ševčík 1; Ph.D. Ing. Ing. Et Jiří Polívka jr. 1 2,3
Authors place of work:
Neurologická klinika, Lékařská fakulta v Plzni, Univerzita Karlova v Praze a Fakultní nemocnice Plzeň
1; Ústav histologie a embryologie, Lékařská fakulta v Plzni, Univerzita Karlova v Praze
2; Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze
3
Published in the journal:
Kardiol Rev Int Med 2013, 15(4): 218-223
Category:
Summary
The treatment and prevention of ischemic cerebrovascular accidents are subject to intensive medical research based on which the recommended treatment procedures used as a support in clinical practice are modified with a certain delay. This paper provides an overview of current information about the prevention of cerebrovascular accidents, which should have been reflected in the clinical decision-making before incorporation into the official recommended procedures. It summarizes the latest information primarily regarding cardioembolic strokes, use of new anticoagulants, and an approach to carotid stenoses based on the results of clinical trials in primary and secondary prevention of cerebrovascular accidents..
Keywords:
ischemic stroke – primary prevention – secondary prevention – anticoagulation therapy – antiplatelet therapy
Zdroje
1. Feigin VL, Lawes CM, Bennett DA et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009; 8: 355–369.2. Kalita Z, Keller O, Bar M et al. Doporučený postup sekundární prevence recidivy po akutní cévní mozkové příhodě: mozkovém infarktu/ tranzitorní ischemické atace a hemoragické cévní mozkové příhodě. Cesk Slov Neurol N 2008; 71/104: 372–378.
3. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. Management ischemické cévní mozkové příhody a tranzitorní ischemické ataky – doporučení European Stroke Organisation (ESO) 2008, aktualizace leden 2009 [online]. Dostupné z: http://www.eso-stroke.org/pdf/ESO_Guidelines_CZ.pdf.
4. Herzig R, Školoudík D, Šaňák D. Management ischemické cévní mozkové příhody a tranzitorní ischemické ataky – doporučení European Stroke Organization (ESO) 2008 – zestručněná česká verze. Cesk Slov Neurol N 2008; 71/104: 364–371.
5. Conroy RM, Pyörälä K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
6. Filipovský J, Widimský J Jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58: 785–801.
7. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press 2013; 22: 193–278.
8. Catapano AL, Reiner Z, De Backer G et al. ESC//EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3–46.
9. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453–463.
10. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–1681.
11. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719–2747.
12. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–1100.
13. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500–1510.
14. Olesen JB, Lip GY, Lindhardsen J et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739–749.
15. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
16. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
17. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
18. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.
19. Čihák R, Haman L, Heinc P. Summary of the 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: Prepared by the Czech Society of Cardiology, Cor et Vasa 2012; 54: e341–e351, dostupné z: http://www.sciencedirect.com/science/article/pii/S0010865012001257?v=s5.
20. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476–484.
21. Huisman MV, Lip GY, Diener HC et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838–847.
22. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis 2013; 35: 391–398.
23. Homma S, Thompson JL, Sanford AR et al. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail 2013; 6: 988–997.
24. Raman G, Moorthy D, Hadar N et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med 2013; 158: 676–685.
25. Ballotta E, Da Giau G, Meneghetti G et al. Progression of atherosclerosis in asymptomatic carotid arteries after contralateral endarterectomy: a 10-year prospective study. J Vasc Surg 2007; 45: 516–522.
26. Halliday A, Harrison M, Hayter E et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010; 376: 1074–1084.
27. Brott TG, Hobson RW 2nd, Howard G et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363: 11–23.
28. Benavente OR, Coffey CS, Conwit R et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382: 507–515.
29. Martínez-García MA, Campos-Rodríguez F, Soler-Cataluña JJ et al. Increased incidence of nonfatal cardiovascular events in stroke patients with sleep apnoea: effect of CPAP treatment. Eur Respir J 2012; 39: 906–912.
30. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624–638.
31. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331–337.
32. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.
33. Benavente OR, Hart RG, McClure LA et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817–825.
34. Chimowitz MI, Lynn MJ, Derdeyn CP et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993–1003.
35. Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–1316.
36. Sandercock PA, Counsell C, Kamal AK. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2009; doi: 10.1002/14651858.CD000024.pub3.
37. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.
38. Furlan AJ, Reisman M, Massaro J et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991–999.
39. Meier B, Kalesan B, Mattle HP et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083–1091.
40. Carroll JD, Saver JL, Thaler DE et al. RESPECT clinical trial. Randomized evaluation of recurrent stroke comparing PFO closure to established current standard of care treatment. Transcatheter Cardiovascular Therapeutics Conference 2012.
41. Gore medical. The Gore REDUCE Clinical Study. [online]. Available from: http://www.clinical.goremedical.com/REDUCE/.
42. Kitsios GD, Dahabreh IJ, Abu Dabrh AM et al. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012; 43: 422–431.
43. Furie KL, Kasner SE, Adams RJ et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227–276.
44. Chambers BR, Donnan GA. Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev 2005; CD001923.
45. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.
46. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–1818.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2013 Číslo 4
Najčítanejšie v tomto čísle
- End organ damage in arterial hypertension and cardiovascular risk
- Syncope of multifactorial etiology or several symptoms of the same disease? - competition case report
- The importance of imaging methods in the cardiovascular disease prevention
- Current approach to the options of primary and secondary prevention of ischemic cerebrovascular accident